Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
First Real-World outcome data of SCLC in Germany – Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

M. Sebastian, M. Reck, R. Fischer, D. Christoph, C. Bernhardt, E. von der Heyde, A. Nusch, P. Ludwig, A. Hipper, J. Hanselmann, T. Medinger, A. Binninger, M. Jänicke, P. Christopoulos, C. Elender, A. Bethge, B. Seese, T. Gauler, C. F. Waller, 2022.

Oncol Res Treat 2022;45(suppl 2):11–346

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2022
Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315).

M Sebastian, F Griesinger, E von der Heyde, S Dörfel, J Wiegand, C Schiefer, C Losem, M Jänicke, A Fleitz, S Zacharias, A Hipper, C Dietel, A Bleckmann, R Benkelmann, M Boesche, C Grah, A Müller, WEE Eberhardt, M Thomas, 2022.

Oncol Res Treat 2022;45(suppl 2):11–346

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2022
First Real-World outcome data of SCLC in Germany – Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

M. Sebastian, M. Reck, R. Fischer, D. Christoph, C. Bernhardt, E. von der Heyde, A. Nusch, P. Ludwig, A. Hipper, J. Hanselmann, T. Medinger, A. Binninger, M. Jänicke, P. Christopoulos, C. Elender, A. Bethge, B. Seese, T. Gauler, C. F. Waller, 2022.

Ann. Onc. 2022, Volume 33, Supplement 7, Pages S545-S1382.

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2022
Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315).

M Sebastian, F Griesinger, E von der Heyde, S Dörfel, J Wiegand, C Schiefer, C Losem, M Jänicke, A Fleitz, S Zacharias, A Hipper, C Dietel, A Bleckmann, R Benkelmann, M Boesche, C Grah, A Müller, WEE Eberhardt, M Thomas, 2022.

Ann. Onc. 2022, Volume 33, Supplement 7, Pages S545-S1382.

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal:
CRISP
2022
Routine care of early breast cancer (stage I-III) in germany. Data of the prospective, intersectoral research platform OPAL.

Welt A, Zahn MO, Wöckel A, Stickeler E, Thoma M, Nusch A, u. a. 2022

Annals of Oncology. 2022;33(187P):S622.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
OPAL
2022
Second-line threapies of patients with early progression under CDK4/6-inhibitor in first-line. Data from the registry platform OPAL.

Marschner N, Harbeck N, Thill M, Stickeler E, Zaiss M, Nusch A, u. a. 2022.

Annals of Oncology. 2022;33(232P):S643.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
OPAL
2022
SMARAGD: The prospective national clinical research platform to study characteristics, treatment and outcomes of patients with ovarian, fallopian tube, primary peritoneal and endometrial cancer in Germany.

Decker T, Wöckel A, Juhasz-Böss I, Zaiss M, Nusch A, Gratzke K, u. a. 2022.

Oncol Res Treat. 2022;45(suppl 2)(V273):72.

Indikation: Endometrial Cancer, Endometriumkarzinom, Ovarialkarzinom, Ovarian Cancer / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
SMARAGD
2022
Routine care of early breast cancer (stage I-III) in Germany – data of the prospective, intersectoral research platform OPAL.

Welt A, Zahn MO, Wöckel A, Stickeler E, Thoma M, Nusch A, u. a.

Oncol.Res.Treat. 2022;45 (suppl 2)(P685):211.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
OPAL
2022
Second-line therapies of patients with early progression under CDK4/6-inhibitor in first-line – data from the registry platform OPAL.

Marschner N, Harbeck N, Thill M, Stickeler E, Zaiss M, Nusch A, u. a. 2022.

Oncol Res Treat. 2022;45(suppl 2)(P345):107.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal:
OPAL
2022
Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Real-World Evidence zu NSCLC Patienten behandelt mit Radiochemotherapie in Deutschland – AIO-TRK-0315.

Eberhardt WEE, Passlick B, Stuschke M, Groeschel A, Christopoulos P, Reck M, et al. 2022.

Oncol Res Treat 2021;44:1–335

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2022